
Sign up to save your podcasts
Or


Ellen: https://www.linkedin.com/in/ellenmaue/
00:00 Intro
01:02 Neuralink FDA application an IDE (Investigational Device Exemption?)
07:13 Full FDA trial timeline?
09:02 Does approval for one indication = approval for all?
10:20 Who selects trial participants?
11:48 Who is the principal investigator?
13:42 FDA equivalent in other countries?
16:00 General trial license possible?
17:46 Expedite timeline by paying more?
21:28 Neuralink trials special?
22:57 Trial process for drugs vs devices?
24:53 IDE, PMA, De Novo?
27:55 Class 1, 2, & 3 devices?
30:44 How often do research groups and companies work together?
34:09 Would merging with Synchron expedite the trials?
41:28 Comparing drug vs device patent life after approval
43:59 Neuralink's breakthrough device designation won't make approval faster
45:05 Additional context for Ellen's job
46:26 Thanks for watching. Please like/ subscribe.
Neura Pod is a series covering topics related to Neuralink, Inc. Topics such as brain-machine interfaces, brain injuries, and artificial intelligence will be explored. Host Ryan Tanaka synthesizes information, shares opinions, and conducts interviews to easily learn about Neuralink and its future.
Support: https://www.patreon.com/neurapod/
Please consider supporting by joining the channel above, or sharing my other company website with retirees: https://www.reterns.com/.
Opinions are my own. Neura Pod receives no compensation from Neuralink and has no affiliation to the company. Edited by: Ryan Tanaka
#Neuralink #ElonMusk #HumanTrials
By Ryan Tanaka4.8
66 ratings
Ellen: https://www.linkedin.com/in/ellenmaue/
00:00 Intro
01:02 Neuralink FDA application an IDE (Investigational Device Exemption?)
07:13 Full FDA trial timeline?
09:02 Does approval for one indication = approval for all?
10:20 Who selects trial participants?
11:48 Who is the principal investigator?
13:42 FDA equivalent in other countries?
16:00 General trial license possible?
17:46 Expedite timeline by paying more?
21:28 Neuralink trials special?
22:57 Trial process for drugs vs devices?
24:53 IDE, PMA, De Novo?
27:55 Class 1, 2, & 3 devices?
30:44 How often do research groups and companies work together?
34:09 Would merging with Synchron expedite the trials?
41:28 Comparing drug vs device patent life after approval
43:59 Neuralink's breakthrough device designation won't make approval faster
45:05 Additional context for Ellen's job
46:26 Thanks for watching. Please like/ subscribe.
Neura Pod is a series covering topics related to Neuralink, Inc. Topics such as brain-machine interfaces, brain injuries, and artificial intelligence will be explored. Host Ryan Tanaka synthesizes information, shares opinions, and conducts interviews to easily learn about Neuralink and its future.
Support: https://www.patreon.com/neurapod/
Please consider supporting by joining the channel above, or sharing my other company website with retirees: https://www.reterns.com/.
Opinions are my own. Neura Pod receives no compensation from Neuralink and has no affiliation to the company. Edited by: Ryan Tanaka
#Neuralink #ElonMusk #HumanTrials

953 Listeners

154,151 Listeners

1,091 Listeners

285 Listeners

2,112 Listeners

1,450 Listeners

9,913 Listeners

72 Listeners

5,475 Listeners

40,452 Listeners

29,184 Listeners

536 Listeners

7,786 Listeners

1,379 Listeners

340 Listeners